AF
KYMR icon

Amalgamated Financial’s Kymera Therapeutics KYMR Stock Holding History

Amalgamated Financial’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$237K Buy
+5,602
New +$237K ﹤0.01% 1834

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's KYMR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Kymera Therapeutics (KYMR) in Q1 2022: 5,602 shares worth $237K. The stake represents ﹤0.01% of the portfolio and ranks #1834 among its holdings.

126 funds tracked by Wall St. Rank hold KYMR as of Q1 2022.

  • Amalgamated Financial held 5,602 shares of Kymera Therapeutics worth $237K as of Q1 2022.
  • Kymera Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Kymera Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1834 holding.
  • 126 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.